Pramlintide vs Cagrilintide

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicPramlintideCagrilintide
What it is

An amylin analogue. The label states that it slows stomach emptying, reduces the rise in glucagon after meals and affects appetite.1

An investigational long-acting amylin analogue from Novo Nordisk, also known as AM833.3,6

FDA status

FDA-approved

FDA-approved as Symlin1,2

FDA-approved. Drugs@FDA lists Symlin with an original approval date of March 16, 2005. The label carries a boxed warning about severe low blood sugar when used with insulin.1,2

Is pramlintide FDA-approved?

In clinical trials

In clinical trials; not FDA-approved3,4,5

Not FDA-approved. FDA states that cagrilintide is not a component of an FDA-approved drug and cannot be used in compounding under federal law.5

Is cagrilintide FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.7

Not among the six peptides the policy lists.7

FDA compounding safety-risk page

Not addressed in this profile’s sources.

Not addressed in this profile’s sources.

Kinds of studies cited

Large randomized human trials

  • Large randomized human trial Three 26- to 52-week randomized, double-blind, placebo-controlled trials in type 1 diabetes, the largest of which randomized 480 participants to pramlintide or placebo alongside insulin.1
  • Large randomized human trial Two randomized, double-blind, placebo-controlled trials in type 2 diabetes, one of which included 327 participants using insulin.1

Large randomized human trials

  • Large randomized human trial A 26-week randomized Phase 2 trial comparing several cagrilintide groups in 706 adults without diabetes, with placebo and liraglutide comparison groups, published in The Lancet.6
  • Large randomized human trial REDEFINE 1, a 68-week randomized Phase 3a trial in 3,417 adults with overweight or obesity that compared the cagrilintide-semaglutide combination with each component alone and with placebo, published in The New England Journal of Medicine.8
  • Registered trial without results A Phase 3 trial of cagrilintide alone in people with overweight or obesity and type 2 diabetes (NCT07220759), listed as active, not recruiting in its August 3, 2026 registry record.4
  • Registered trial without results A Phase 3 trial of cagrilintide alone in overweight or obesity (NCT07745504), listed as not yet recruiting in its August 4, 2026 registry record.9
Records collected

5 ClinicalTrials.gov records and 48 PubMed records collected

7 ClinicalTrials.gov records and 6 PubMed records collected

Area of study

Metabolic and weight1

Metabolic and weight3

Latest dated events
  1. DailyMed publishes the Symlin label version cited on this page.1
  2. FDA approves Symlin, according to Drugs@FDA.2
  1. FDA’s page on unapproved GLP-1 drugs, which says cagrilintide cannot be used in compounding, is updated, as shown by its content-current date.5
  2. REDEFINE 1 results for the cagrilintide-semaglutide combination are published in The New England Journal of Medicine.8
  3. Results of the Phase 2 cagrilintide trial are published in The Lancet.6

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    SYMLINPEN (pramlintide acetate) injection · SPL version 18 · published 2024-08-20 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  2. 2
    Drugs@FDA application NDA021332 · original submission status AP · 2005-03-16 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  3. 3
    Cagrilintide and CagriSema in Children and Adolescents With Excess Body Weight · record history version 5 · last update posted 2026-07-17 ↗

    ClinicalTrials.gov · Official source · Source checked July 22, 2026

  4. 4
    ClinicalTrials.gov record NCT07220759 · retained source version 2026-08-03:50fb10a6adbd81022c8cc1ee950e283b46f97533acbf5a944399ee4e77eaceb1 ↗

    ClinicalTrials.gov · Official source · Source checked August 14, 2026

  5. 5
    FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  6. 6
    Once-weekly cagrilintide for weight management in people with overweight and obesity: a dose-finding phase 2 trial (2021) · PMID 34798060 ↗

    The Lancet · Official source · Source checked November 14, 2026

  7. 7
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  8. 8
    Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1, 2025) · PMID 40544433 ↗

    The New England Journal of Medicine · Official source · Source checked November 14, 2026

  9. 9
    ClinicalTrials.gov record NCT07745504 · retained source version 2026-08-04:624035118e08abe47d4c56faae694b0047f077f295c17f9043520d41dcfc3f70 ↗

    ClinicalTrials.gov · Official source · Source checked August 14, 2026